Formula I Compounds for Multi-Drug Resistant Bacterial Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The increasing prevalence of multi-drug resistant bacterial infections, particularly among Gram-positive and Gram-negative pathogens, has led to a scarcity of effective antibacterial agents, with few new drugs being developed to address this crisis, resulting in limited treatment options and significant health and economic burdens.
Innovation Solution
Development of specific compounds of Formula I, or their stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs, which exhibit novel mechanisms of action against bacterial infections, potentially offering alternative treatments for multi-resistant bacteria.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antibacterial agents are used, then existing treatment options are available, but multi-drug resistance renders them increasingly ineffective
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of antibacterial agents through systematic variation of molecular components (R1-R28 substituents, heterocyclic rings, functional groups) to create compounds with novel mechanisms of action that evade resistance mechanisms of existing drugs
Solution Approach 2:
The invention creates composite molecular structures combining diverse chemical moieties (beta-lactam rings, carbapenem cores, heterocyclic substituents, hydrophilic groups) to produce antibacterial agents with enhanced activity against multidrug-resistant pathogens while maintaining selective toxicity
2Adaptability or versatility
If new antibacterial agents are developed, then treatment options for resistant bacteria expand, but drug development investment has declined for 15 years
Solution Approach 1:
The patent performs preliminary action by establishing a comprehensive computational framework before experimental validation, using in silico docking, molecular dynamics simulations, and predictive toxicity modeling to identify and optimize lead compounds, thereby accelerating the drug discovery pipeline
Solution Approach 2:
The invention replaces traditional experimental trial-and-error drug discovery with computational chemistry and AI-driven molecular design, using quantum mechanical calculations, machine learning algorithms, and high-throughput virtual screening to predict drug efficacy and safety profiles
3Reliability
If existing antibacterial classes are used, then treatment is possible, but few novel classes are moving through development pipeline
Solution Approach 1:
The patent applies segmentation by dividing the antibacterial agent into distinct functional modules: core beta-lactam carbapenem structure, heterocyclic substituent groups (R1-R4), hydrophilic functional groups (R5-R8), and terminal moieties (R9-R28), allowing independent optimization of each component for specific biological activities
Solution Approach 2:
The invention explores another dimension by transitioning from two-dimensional chemical structures to three-dimensional conformational analysis, using molecular docking simulations and structural biology data to predict binding modes and interaction mechanisms with bacterial targets
Data Source
Figure 1
Figure 1
Figure 1
AI summary
The invention provides compounds of Formula I, and methods of treating or preventing a bacterial infection in a subject using a compound of Formula I. The invention also provides the use of a compound of Formula I in the manufacture of a medicament for the treatment of a bacterial infection in a subject. The invention further provides a medical device when used in a method of treating or preventing a bacterial infection in a subject and to a medical device comprising the composition of the invention.